Pembrolizumab Post-IMRT for Thyroid Cancer

Recruiting in Palo Alto (17 mi)

Overseen byMaria Cabanillas, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

Stay on Your Current Meds

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial tests if pembrolizumab, given after radiation therapy, can help patients with advanced anaplastic thyroid cancer in the neck live longer without their disease getting worse. Pembrolizumab works by boosting the immune system to attack cancer cells and is used to treat various cancers.

Research Team

Maria Cabanillas, MD

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for adults with stage IVB anaplastic thyroid cancer (ATC) who have completed radiation therapy, possibly with chemotherapy. They must be in good health overall, not pregnant or breastfeeding, and willing to use contraception. Those with certain prior treatments or immunodeficiencies, recent vaccinations, or specific genetic mutations are excluded.

Inclusion Criteria

Written informed consent for the trial

My cancer is advanced but hasn’t spread to my neck.

I am 18 or older with a diagnosis of anaplastic thyroid cancer.

See 4 more

Exclusion Criteria

I have not received a live vaccine in the last 30 days.

I have an immune system disorder or have been on steroids or other immune-weakening drugs in the last week.

I have had previous treatments targeting my immune system.

See 4 more

Treatment Details

Interventions

Pembrolizumab (PD-1 Inhibitor)

Trial OverviewThe trial tests pembrolizumab as an additional treatment after radiation for ATC. It aims to see how long patients can live without their cancer getting worse after this combination of therapies. Participants will receive pembrolizumab following either high-dose (>51 Gy) or lower-dose (<50 Gy) radiation.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: PembrolizumabExperimental Treatment1 Intervention

The infusions are given every 6 weeks